

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/09, 31/135	A1	(11) International Publication Number: WO 99/55357 (43) International Publication Date: 4 November 1999 (04.11.99)
(21) International Application Number: PCT/EP99/02133 (22) International Filing Date: 29 March 1999 (29.03.99) (30) Priority Data: 60/082,743 23 April 1998 (23.04.98) US (71) Applicant: ASTA MEDICA AKTIENGESELLSCHAFT [DE/DE]; An der Pikardie 10, D-01277 Dresden (DE). (72) Inventors: ENGEL, Jürgen; Erlenweg 3, D-63755 Alzenau (DE). RIETHMÜLLER-WINZEN, Hilde; Mittelweg 27, D-60318 Frankfurt (DE). REISSMANN, Thomas; Mass- bornstrasse 44, D-60437 Frankfurt (DE).		(81) Designated States: AU, BG, BR, BY, CA, CN, CZ, EE, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, UZ, YU, ZA, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: METHOD FOR THE TREATMENT OF FERTILITY DISORDERS (57) Abstract In the method of therapeutic management of infertility by intrauterine insemination the improvement consisting of a) the dose-dependent suppression of endogenous gonadotropins, especially LH, with a LH-RH Antagonist allowing the maintenance of physiological oestrogen levels, b) exogeneous stimulation of the ovarian follicle growth, c) ovulation induction with HCG, native LHRH, LHRH-Agonists or recombinant LH, d) intrauterine insemination by sperm injection. The LHRH Antagonists may be preferably Cetrorelix or Antarelix. The stimulation is performed by administration of HMG or recombinant FSH with or without recombinant LH or with antiestrogens as for example Clomiphen as well as with the combination of antiestrogens as for example Clomiphen with gonadotropins.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Method for the treatment of fertility disorders

One of the ethical problems of more recent times is the increasing sterility and unwanted childlessness of many couples. With respect to the therapy of these fertility disorders, inter alia, the following treatment methods of artificial fertilization have been established:

1. Substitution therapy - applied in patients with hypogonadotropic amenorrhoea
- 10 2. Stimulation therapy - given to anovulatory patients with active, albeit deranged hypothalamic pituitary-ovarian axis
3. Regulation therapy - employed in women with PCOD
4. Hyperstimulation therapy - used in IVF, gamete
15 intrafallopian transfer (GIFT), tubal embryo transfer (TET), intracytoplasmatic sperm injection (ICSI) and intrauterine insemination (IUI).

The present invention especially relates to the improvement of the method of artificial sperm cell transfer in the uterus, i.e. the fertilization by intrauterine insemination (IUI) mentioned under item 4.

For the methods under items 2 and 4, it is necessary to stimulate follicle growth, which is achieved by the administration of gonadotropins, e.g. HMG, FSH and LH, with or without preliminary therapy with clomiphene.

It has further proved that the risk of luteinization by a premature LH surge, which leads to unfavourable implantation conditions and relatively low pregnancy rates, can be decreased by complete suppression of the endogenous gonadotropins using GnRH agonists (Garcia et al., 1984; Navot et al., 1991; Hoffmann et al., 1993).

For the control of ovarian stimulation with subsequent induction of ovulation, with the aim of obtaining fertilizable egg cells, both recombinant FSH and HMG and FSH and HMG obtained from urine are employed.

- 2 -

In connection with IUI, it is also desirable to control follicle growth and to specifically trigger ovulation.

5 The statements in the specialist literature about the therapeutic accompaniment of IUI, in particular using GnRH analogues, are mainly negative, such as, for example, the following:

1. IUI after ovarian stimulation with clomiphene may be important as the 1st choice of therapy, provided
10 the male partner has a normal spermiogram (Hum. Reprod. 1997; July; 12(7):1458-1463).
2. GnRH agonists/HMG stimulation, however, may be ineffective in routine IUI. Treatment with GnRH agonists with maximum suppression of the
15 endogenous gonadotropins requires a relatively long treatment period (about 3 weeks) and leads to an increased consumption of HMG and is associated with side effects.
3. Reports also exist which confirm that an increase
20 in the pregnancy rate is not achieved by the use of GnRH agonists/HMG against HMG alone for IUI treatment in the case of unclarified infertility (Hum. Reprod. 1994 June 9(6) 1043-1047).
4. The cost differences of GnRH-a/HMG stimulation
25 compared with clomiphene/HMG is indicated by Finnish authors in Eur. J. Obstet. Gynecol. Reprod. Biol. 1997 July 74: GnRH-a/HMG stimulation is not cost-effective in routine IUI therapy.

30 In a study by Diedrich et al. from 1994 Hum. Reprod. 1994 May; 9(5), the suppression of the undesired, premature LH surge by cetorelix during ovarian stimulation with HMG and the on-time induction of ovulation was described in the context of a COS-ART
35 study.

It was possible to shorten the length of the treatment period using this LHRH antagonist and the partial dose-dependent suppression of the endogenous gonadotropins additionally proved advantageous, since it was possible

to reduce the consumption in comparison to the use of agonists of HMG.

- The object of the invention is therefore to improve,
5 i.e. to make inexpensive and more effective, the treatment method of intrauterine insemination known per se and thus in the end to fulfil the desire for children of many couples.
- 10 It has now been found that the treatment method of IUI can be improved by carrying out a partial suppression of the endogenous gonadotropins, which can only be achieved by means of LHRH antagonists, preferably
15 cetrorelix or antarelix. At the same time, follicle growth is stimulated by means of urinary or recombinant FSH, HMG or clomiphene, or a combination thereof. Subsequently, ovulation can be triggered at a desired time by means of HCG, native LHRH, LHRH agonists or
20 recombinant LH. Surprisingly, this takes place when the dominant follicle has reached a diameter of about 16-18 mm. Intrauterine sperm injection then takes place with the aim of intracorporeal fertilization. It is possible in this way to carry out a stimulation treatment which is less stressful for the patient and
25 guarantees a high degree of safety with respect to the ovulation time and leads to a saving in cost.

Claims:

1. In the method of therapeutic management of infertility by intrauterine insemination, the improvement consisting of
 - a) the dose-dependent suppression of endogenous gonadotropins, especially LH, with an LH-RH antagonist allowing the maintenance of physiological oestrogen levels
 - b) exogenous stimulation of the ovarian follicle growth
 - c) ovulation induction with HCG, native LHRH, LHRH agonists or recombinant LH.
 - d) intrauterine insemination by sperm injection.
2. The method of therapeutic management of infertility by intrauterine insemination according to claim 1 in which the LHRH antagonist is cetrorelix.
3. The method of therapeutic management of infertility by intrauterine insemination according to claim 1 in which the LHRH antagonist is antarelix.
4. The method of therapeutic management of infertility by intrauterine insemination according to claim 1 in which the stimulation is performed by administration of urinary or recombinant FSH or HMG, with or without recombinant LH.
5. The method of therapeutic management of infertility by intrauterine insemination according to claim 1 in which the ovarian stimulation is achieved with antioestrogens as for example clomiphene.
6. The method of therapeutic management of infertility by intrauterine insemination according

to claim 1 in which the ovarian stimulation is achieved with the combination of antioestrogens as for example clomiphene with gonadotropins.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/02133

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K38/09 A61K31/135

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 611 572 A (ASTA MEDICA AG) 24 August 1994 (1994-08-24) *cf. abstract and page 3, lines 47-52, page 4, lines 15-21*	1-6
Y	EP 0 788 799 A (ASTA MEDICA AG) 13 August 1997 (1997-08-13) *cf. abstract, col. 1, lines 11-14, 39-54, col. 2, lines 40-43*	1-6
Y	DE 196 04 231 A (SCHERING AG) 31 July 1997 (1997-07-31) *cf. abstract, col. 1, first para., col. 2, lines 15-28*	1-6
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

6 August 1999

Date of mailing of the international search report

31/08/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Stoltner, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/02133

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BOUCHARD P., ET AL. : " Endocrine features of combined gonadotropin and GNRH antagonist ovulation induction" OVUL. IND. UPDATE '98, PROC. WORLD CONF., 2ND, 1998,1997, pages 115-119, XP002111491 *cf. introduction* ---	1-6
A	US 5 130 137 A (CROWLEY JR WILLIAM F) 14 July 1992 (1992-07-14) *cf. col. 2, last para. bridging with col. 3, lines 1-7* -----	1-6

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/02133

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0611572 A	24-08-1994	DE 4305225 A	25-08-1994
		AU 671881 B	12-09-1996
		AU 5523594 A	25-08-1994
		BR 9400617 A	27-09-1994
		CA 2115943 A	20-08-1994
		CN 1112019 A	22-11-1995
		CZ 9400312 A	14-09-1994
		FI 940779 A	20-08-1994
		HR 940117 A	31-08-1996
		HU 67117 A	28-02-1995
		JP 6271476 A	27-09-1994
		MX 9401312 A	31-08-1994
		NO 940564 A	22-08-1994
		NZ 250906 A	27-07-1997
		NZ 314707 A	25-02-1999
		SG 46632 A	20-02-1998
		SI 9400087 A	31-12-1994
		SK 19594 A	07-09-1994
		ZA 9401136 A	29-08-1994
EP 0788799 A	13-08-1997	JP 9227404 A	02-09-1997
DE 19604231 A	31-07-1997	AU 1596997 A	22-08-1997
		CN 1209750 A	03-03-1999
		CZ 9802391 A	11-11-1998
		WO 9727863 A	07-08-1997
		EP 0877621 A	18-11-1998
		NO 983465 A	18-09-1998
		PL 328066 A	04-01-1999
US 5130137 A	14-07-1992	AU 6353790 A	11-03-1991
		WO 9101748 A	21-02-1991

INTERNATIONALER RECHERCHENBERICHT

Int. J.ionales Aktenzeichen

PCT/EP 99/02133

A. KLASSIFIZIERUNG DES ANMELDUNGSGEGENSTANDES IPK 6 A61K38/09 A61K31/135		
Nach der internationalen Patentklassifikation (IPK) oder nach der nationalen Klassifikation und der IPK		
B. RECHERCHIERTE GEBIETE Recherchierter Mindestprüfstoff (Klassifikationssystem und Klassifikationssymbole) IPK 6 A61K		
Recherchierte aber nicht zum Mindestprüfstoff gehörende Veröffentlichungen, soweit diese unter die recherchierten Gebiete fallen		
Während der internationalen Recherche konsultierte elektronische Datenbank (Name der Datenbank und evtl. verwendete Suchbegriffe)		
C. ALS WESENTLICH ANGESEHENE UNTERLAGEN		
Kategorie*	Bezeichnung der Veröffentlichung, soweit erforderlich unter Angabe der in Betracht kommenden Teile	Betr. Anspruch Nr.
Y	EP 0 611 572 A (ASTA MEDICA AG) 24. August 1994 (1994-08-24) Zusammenfassung und Seite 3, Zeilen 47-52, Seite 4, Zeilen 15-21. ---	1-6
Y	EP 0 788 799 A (ASTA MEDICA AG) 13. August 1997 (1997-08-13) Zusammenfassung, Spalte 1, Zeilen 11-14, 39-54, Spalte 2, Zeilen 40-43. ---	1-6
Y	DE 196 04 231 A (SCHERING AG) 31. Juli 1997 (1997-07-31) Zusammenfassung, Spalte 1, erster Abschnitt, Spalte 2, Zeilen 15-28. ---	1-6
	-/--	
<input checked="" type="checkbox"/> Weitere Veröffentlichungen sind der Fortsetzung von Feld C zu entnehmen		
<input checked="" type="checkbox"/> Siehe Anhang Patentfamilie		
* Besondere Kategorien von angegebenen Veröffentlichungen : "A" Veröffentlichung, die den allgemeinen Stand der Technik definiert, aber nicht als besonders bedeutsam anzusehen ist "E" älteres Dokument, das jedoch erst am oder nach dem internationalen Anmeldedatum veröffentlicht worden ist "L" Veröffentlichung, die geeignet ist, einen Prioritätsanspruch zweifelhaft erscheinen zu lassen, oder durch die das Veröffentlichungsdatum einer anderen im Recherchenbericht genannten Veröffentlichung belegt werden soll oder die aus einem anderen besonderen Grund angegeben ist (wie ausgeführt) "O" Veröffentlichung, die sich auf eine mündliche Offenbarung, eine Benutzung, eine Ausstellung oder andere Maßnahmen bezieht "P" Veröffentlichung, die vor dem internationalen Anmeldedatum, aber nach dem beanspruchten Prioritätsdatum veröffentlicht worden ist "T" Spätere Veröffentlichung, die nach dem internationalen Anmeldedatum oder dem Prioritätsdatum veröffentlicht worden ist und mit der Anmeldung nicht kollidiert, sondern nur zum Verständnis des der Erfindung zugrundeliegenden Prinzips oder der ihr zugrundeliegenden Theorie angegeben ist "X" Veröffentlichung von besonderer Bedeutung; die beanspruchte Erfindung kann allein aufgrund dieser Veröffentlichung nicht als neu oder auf erfinderscher Tätigkeit beruhend betrachtet werden "Y" Veröffentlichung von besonderer Bedeutung; die beanspruchte Erfindung kann nicht als auf erfinderscher Tätigkeit beruhend betrachtet werden, wenn die Veröffentlichung mit einer oder mehreren anderen Veröffentlichungen dieser Kategorie in Verbindung gebracht wird und diese Verbindung für einen Fachmann naheliegend ist "Z" Veröffentlichung, die Mitglied derselben Patentfamilie ist		
Datum des Abschlusses der internationalen Recherche 6. August 1999		Absenddatum des internationalen Recherchenberichts 31/08/1999
Name und Postanschrift der internationalen Recherchenbehörde Europäisches Patentamt, P.B. 5816 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Bevollmächtigter Bediensteter Stoltner, A

INTERNATIONALER RECHERCHENBERICHT

Inte.ionales Aktenzeichen

PCT/EP 99/02133

C.(Fortsetzung) ALS WESENTLICH ANGESEHENE UNTERLAGEN		
Kategorie ²	Bezeichnung der Veröffentlichung, soweit erforderlich unter Angabe der in Betracht kommenden Teile	Betr. Anspruch Nr.
Y	BOUCHARD P., ET AL. : " Endocrine features of combined gonadotropin and GNRH antagonist ovulation induction" OVUL. IND. UPDATE '98, PROC. WORLD CONF., 2ND, 1998,1997, Seiten 115-119, XP002111491 Einführung. ---	1-6
A	US 5 130 137 A (CROWLEY JR WILLIAM F) 14. Juli 1992 (1992-07-14) Spalte 2, letzter Abschnitt "bridging with col 3" Zeilen 1-7. -----	1-6

INTERNATIONALER RECHERCHENBERICHT

Angaben zu Veröffentlichungen, die zur selben Patentfamilie gehören

Internationales Aktenzeichen

PCT/EP 99/02133

Im Recherchenbericht angeführtes Patentdokument	Datum der Veröffentlichung	Mitglied(er) der Patentfamilie	Datum der Veröffentlichung
EP 0611572 A	24-08-1994	DE 4305225 A	25-08-1994
		AU 671881 B	12-09-1996
		AU 5523594 A	25-08-1994
		BR 9400617 A	27-09-1994
		CA 2115943 A	20-08-1994
		CN 1112019 A	22-11-1995
		CZ 9400312 A	14-09-1994
		FI 940779 A	20-08-1994
		HR 940117 A	31-08-1996
		HU 67117 A	28-02-1995
		JP 6271476 A	27-09-1994
		MX 9401312 A	31-08-1994
		NO 940564 A	22-08-1994
		NZ 250906 A	27-07-1997
		NZ 314707 A	25-02-1999
		SG 46632 A	20-02-1998
		SI 9400087 A	31-12-1994
		SK 19594 A	07-09-1994
		ZA 9401136 A	29-08-1994
EP 0788799 A	13-08-1997	JP 9227404 A	02-09-1997
DE 19604231 A	31-07-1997	AU 1596997 A	22-08-1997
		CN 1209750 A	03-03-1999
		CZ 9802391 A	11-11-1998
		WO 9727863 A	07-08-1997
		EP 0877621 A	18-11-1998
		NO 983465 A	18-09-1998
		PL 328066 A	04-01-1999
US 5130137 A	14-07-1992	AU 6353790 A	11-03-1991
		WO 9101748 A	21-02-1991